Introduction: The effects of medical therapy or surgery on bladder and prostatic resistive indices (RIs) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in the present study. Patients and Methods: A total of 124 consecutive LUTS/BPH patients who were candidates for medical therapy (alfuzosin 10 mg once daily, n = 66) or surgery (transurethral prostatectomy (TUR-P), n = 58) were prospectively included. Baseline assessment of patients was performed with the International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), and prostatic and bladder RIs measured using power Doppler imaging (PDI). All patients were re-evaluated 3 months after treatment measuring the same parameters. Results: Following medical therapy, mean IPSS (17.2 ± 5.1 vs. 8.3 ± 5.3, p = 0.0001), postvoiding residual (PVR) urine (80.0 ± 80.5 vs. 40.3 ± 38.6, p = 0.0001), and prostatic RI (0.73 ± 0.1 vs. 0.70 ± 0.1, p = 0.0001) were decreased, Qmax (13.7 ± 4.2 vs. 16.9 ± 5.9, p = 0.0001) was increased, and bladder RI remained unchanged (0.70 ± 0.1 vs. 0.70 ± 0.1, p = 0.68). Mean IPSS (25.3 ± 5.6 vs. 6.0 ± 4.5, p = 0.0001), PVR urine volume (134.5 ± 115.5 vs. 35.7 ± 25.9, p = 0.0001), and prostatic (0.78 ± 0.1 vs. 0.67 ± 0.04, p = 0.0001) and bladder RIs (0.72 ± 0.1 vs. 0.64 ± 0.04, p = 0.005) were decreased, and Qmax (8.0 ± 4.5 vs. 17.2 ± 8.2, p = 0.0001) was increased after TUR-P. Conclusions: Our results demonstrated that TUR-P decreased both prostatic and bladder RIs, while α-blocker therapy did not change bladder RI in the early posttreatment period in LUTS/BPH patients.

Keywords:
Alpha-adrenergic blockers, Benign prostatic hyperplasia, Doppler ultrasonography, Transurethral prostate resections
1.
Park HJ, Won JE, Sorsaburu S, Rivera PD, Lee SW: Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health 2013;31:193-207.
2.
Robert G, Descazeaud A, Azzouzi R, et al: Impact of lower urinary tract symptoms on discomfort in men aged between 50 and 80 years. Urol Int 2010;84:424-429.
3.
Oelke M, Bachmann A, Descazeaud A, et al; European Association of Urology: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-140.
4.
Chen JS, Chang CH, Yang WH, Kao YH: Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study. BJU Int 2012;110:896-901.
5.
Konstantinidis C, Samarinas M, Andreadakis S, Xanthis S, Skriapas K: Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin - a prospective study. Urol Int 2013;90:156-160.
6.
Santos Dias J: Benign prostatic hyperplasia: clinical manifestations and evaluation. Tech Vasc Interv Radiol 2012;15:265-269.
7.
Oh MM, Kim JW, Kim JJ, Moon du G: Is there a correlation between the outcome of transurethral resection of prostate and preoperative degree of bladder outlet obstruction? Asian J Androl 2012;14:556-559.
8.
Klingler HC, Madersbacher S, Djavan B, Schatzl G, Marberger M, Schmidbauer CP: Morbidity of the evaluation of the lower urinary tract with transurethral multichannel pressure-flow studies. J Urol 1998;159:191-194.
9.
Tsuru N, Kurita Y, Masuda H, Suzuki K, Fujita K: Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy. Int J Urol 2002;9:427-430.
10.
Kojima M, Watanabe H, Watanabe M, Okihara K, Naya Y, Ukimura O: Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med Biol 1997;23:1305-1309.
11.
Ozdemir H, Onur R, Bozgeyik Z, Orhan I, Ogras MS, Ogur E: Measuring resistance index in patients with BPH and lower urinary tract symptoms. J Clin Ultrasound 2005;33:176-180.
12.
Ozden C, Gunay I, Deren T, et al: Effect of transurethral resection of prostate on prostatic resistive index. Urol Int 2010;84:191-193.
13.
Zhang X, Li G, Wei X, et al: Resistive index of prostate capsular arteries: a newly identified parameter to diagnose and assess bladder outlet obstruction in patients with benign prostatic hyperplasia. J Urol 2012;188:881-887.
14.
Pinggera GM, Mitterberger M, Steiner E, et al: Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int 2008;102:470-474.
15.
Pinggera GM, Mitterberger M, Pallwein L, et al: Alpha-blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 2008;101:319-324.
16.
Amiel GE, Slawin KM: Newer modalities of ultrasound imaging and treatment of the prostate. Urol Clin North Am 2006;33:329-337.
17.
Murphy KJ, Rubin JM: Power Doppler: it's a good thing. Semin Ultrasound CT MR 1997;18:13-21.
18.
Shinbo H, Kurita Y, Nakanishi T, et al: Resistive index: a newly identified predictor of outcome of transurethral prostatectomy in patients with benign prostatic hyperplasia. Urology 2010;75:143-147.
19.
Fultz NH, Herzog AR: Epidemiology of urinary symptoms in the geriatric population. Urol Clin North Am 1996;23:1-10.
20.
Shenfeld OZ, Meir KS, Yutkin V, Gofrit ON, Landau EH, Pode D: Do atherosclerosis and chronic bladder ischemia really play a role in detrusor dysfunction of old age? Urology 2005;65:181-184.
21.
Azadzoi KM, Goldstein I, Siroky MB, Traish AM, Krane RJ, Saenz de Tejada I: Mechanisms of ischemia-induced cavernosal smooth muscle relaxation impairment in a rabbit model of vasculogenic erectile dysfunction. J Urol 1998;160:2216-2222.
22.
Murray SP, Stoney RJ: Chronic visceral ischemia. Cardiovasc Surg 1994;2:176-179.
23.
Koskimäki J, Hakama M, Huhtala H, Tammela TL: Association of smoking with lower urinary tract symptoms. J Urol 1998;159:1580-1582.
24.
Willder JM, Walker VC, Halbert GL, et al: Body mass index predicts failure of surgical management in benign prostatic hyperplasia. Urol Int 2013;90:150-155.
25.
Willder JM, Walker VC, Halbert GL, et al: The prognostic use of inflammation and tissue necrosis in benign prostatic hyperplasia. Urol Int 2013;91:19-25.
26.
Levin RM, Levin SS, Zhao Y, Buttyan R: Cellular and molecular aspects of bladder hypertrophy. Eur Urol 1997;32:15-21.
27.
Belenky A, Abarbanel Y, Cohen M, Yossepowitch O, Livne PM, Bachar GN: Detrusor resistive index evaluated by Doppler ultrasonography as a potential indicator of bladder outlet obstruction. Urology 2003;62:647-650.
28.
Goi Y, Tomiyama Y, Nomiya M, Sagawa K, Aikawa K, Yamaguchi O: Effects of silodosin, a selective α1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction. J Urol 2013;190:1116-1122.
29.
Kim JW, Jang HA, Bae JH, Lee JG: Effects of coenzyme Q10 on bladder dysfunction induced by chronic bladder ischemia in a rat model. J Urol 2013;189:2371-2376.
30.
Sawada N, Nomiya M, Hood B, Koslov D, Zarifpour M, Andersson KE: Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol 2013;64:664-671.
31.
Wada N, Watanabe M, Kita M, Matsumoto S, Kakizaki H: Analysis of bladder vascular resistance before and after prostatic surgery in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Neurourol Urodyn 2012;31:659-663.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.